

**Supplemental Table 2** Clinicopathological, genetic and prognostic characteristics of adult patients with myeloid sarcoma

case	age range / gender	survival (months) / follow up	accompanying haematologic disease	localization	CNS involvement	cytogenetic	FISH	treatment	response
3	35-40/F	28/dead	w/si AML	nasopharynx	positive	47,XX,i(7)(q10),+8,+20,-17[5]	inv(16) 17p13.1 locus P53 gene deletion chromosome 8 trisomy 11q23 locus KMT2A translocation	AML-type CT	CR
5	60-65/M	54/alive	none	lymph node	.	ND	ND	AML-type CT	CR
6	70-75/M	1/dead	w/si AML	GIS	.	ND	ND	AML-type CT	
7	80-85/M	11/dead	w/p MDS	lymph node	.	46,XY	ND	RT	
8	65-70/F	43/alive	none	GIS	.	46,XX	normal	AML-type CT	CR
9	25-30/M	7/dead	w/p MPN	soft tissue	.	48,XY,t(9;22)(q34;q12.1),der(22)8[18]/46,XY,t(9;22)(q34;q12.1)[2]	ND	AML-type CT	refractory
11	18-20/M	6/dead	none	bone	.	ND	ND	AML-type CT	
12	30-35/M	69/alive	none	lymph node	.	ND	ND	RT	CR
13	55-60/M	90/alive	none	bone	.	ND	ND	AML-type CT	CR
14	50-55/M	0/dead	w/p AML-MDS	soft tissue	.	46,XY,-21,+MARKER	ND		
15	40-45/M	4/dead	none	skin	.	46,XY	t(9;22) negative	no treatment	exitus due to indeterminate cause
16	25-30/M	2/dead	w/p MDS	lymph node	.	ND	ND	AML-type CT	
17	60-65/M	0/dead		soft tissue	.	ND	ND	AML-type CT	
18	70-75/M		w/p MPN	parapharynx	.	ND	ND		
19	70-75/F		none	lymph node and nasopharynx	.	ND	ND		
20	40-45/M		none	lymph node	.	ND	ND	AML-type CT	
21	35-40/M		w/p MPN	bladder and soft tissue	.	ND	ND	AML-type CT	

22	20-25/M	6/dead	w/s AML	lymph node	.	46,XY[1]/47,XY,2[4]/46,XY,t(12;13)[3][cp8]	t(9;22) negative	RT	refractory
23	40-45/M	6/dead		mediastinum	.	ND	ND	AML-type CT	
25	25-30/F		w/si AML	breast	.	ND	ND	AML-type CT	
26	45-50/F	8/dead		skin	.	ND	ND	AML-type CT	
27	55-60/M	3/dead		lymph node	.	ND	ND	AML-type CT	
29	30-35/F	4/dead	w/p MDS	skin	negative	ND	ND	AML-type CT + Allo-SCT	haematologic relapse
30	45-50/M	1/dead		soft tissue	.	ND	ND	AML-type CT	
34	30-35/M	60/dead	none	GIS	.	ND	ND	AML-type CT + Allo-SCT	CR
35	55-60/M		w/si AML	GIS	negative	ND	ND		
36	30-35/M	36/alive	w/p AML	brain	positive	46,XY	t(15;17) negative, complex karyotype of chromosome 15 and 17	AML-type CT + Allo-SCT	CR
37	40-45/M		w/p AML	nasopharynx and lymph node	.	ND	ND	AML-type CT	
38	40-45/F	1/dead	none	brain	.	ND	ND	AML-type CT	
39	40-45/F	34/alive	none	breast	.	ND	ND	AML-type CT	
40	50-55/F	81/alive	none	soft tissue and skin	.	ND	ND	RT	CR
41	60-63/F	8/alive	w/p MDS-MPN-MF	lymph node	.	ND	ND	Azasitidin	CR
43	70-75/F	2/dead	w/p AML	parapharynx	.	ND	20q12 trisomy	AML-type CT	exitus due to indeterminate cause
44	20-25/F	15/alive	w/si AML	lymph node	.	ND	ND	AML-type CT	
45	80-85/F	11/dead		lymph node	.	ND	ND	AML-type CT	

**Abbreviations:** M, male; F, female; AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; MF, myelofibrosis; CNS, Central nervous system; GIS, gastrointestinal system; CT, chemotherapy; RT, radiotherapy; w/s, with subsequent diagnosis; allo-SCT, allogeneic stem cell transplantation; CR, complete remission; w/si, with simultaneous diagnosis; w/p, with previous diagnosis; “.”, not investigated; ND, not done.